stockrow
Friday 6 November 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +72.9%
- Free cash flow
- +5.54%
- Total debt
- +0.87%
Quarter to September 2026, against a year earlier
13.26
0.29
−2.14%
Follow NVCR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.20 | 1.84 | 2.51 | 2.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(80.06) | (92.05) | 216.13 | 82.18 | |
P/B ratio |
4.23 | 3.76 | 5.20 | 5.31 | |
Price to Tangible BV |
4.23 | 3.76 | 5.20 | 5.31 | |
EV/Sales |
1.80 | 1.54 | 2.15 | 2.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.04) | (38.59) | (533.92) | (2,195.95) | |
EV/FCF |
(15.58) | (21.58) | (59.09) | (64.43) | |
Quick Ratio |
2.71 | 2.70 | 2.70 | 2.34 | |
Current Ratio |
2.90 | 2.90 | 2.89 | 2.49 | |
Net Debt/EBITDA |
6.57 | 3.14 | 28.77 | 63.53 | |
Debt/Assets |
24.25% | 29.82% | 24.63% | 23.69% | |
Debt/Equity |
0.57 | 0.71 | 0.58 | 0.56 | |
Asset Turnover |
0.64 | 0.66 | 0.69 | 0.66 | |
Operating CF/Net income |
0.73 | 0.19 | (0.52) | (2.17) | |
Capex/Depreciation |
(10.37) | (3.42) | (4.03) | (3.83) | |
Interest Coverage |
(72.00) | (36.68) | (5.59) | (3.61) | |
Research and Development Expense of Revenue |
34.93% | 33.52% | 28.02% | 30.04% | |
Selling, General and Administrative Expense of Revenue |
64.06% | 82.85% | 55.34% | 50.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.37% | 36.20% | 9.27% | 9.04% | |
Graham Net Nets |
0.13 | 0.14 | 0.10 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.44%) | (14.04%) | (8.58%) | (6.64%) | |
Free Cash Flow Yield |
(5.25%) | (3.86%) | (1.45%) | (1.32%) | |
Revenue per Share |
1.56 | 1.52 | 1.58 | 1.66 | |
Operating CF per Share |
(0.16) | (0.12) | 0.07 | 0.19 | |
Capex per Share |
(0.04) | (0.05) | (0.06) | (0.06) | |
Free Cash Flow per Share |
(0.21) | (0.16) | 0.01 | 0.13 | |
Cash per Share |
4.10 | 3.87 | 3.88 | 4.06 | |
Shareholders Equity per Share |
3.05 | 2.90 | 2.91 | 3.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.05 | 2.90 | 2.91 | 3.00 | |
Free Cash Flow |
(22.90) | (18.67) | 1.22 | 15.75 | |
Working Capital |
423.50 | 414.09 | 417.81 | 402.86 | |
Capital Expenditures |
(4.90) | (5.15) | (6.92) | (6.92) | |
Net Current Asset Value |
182.87 | 174.45 | 181.42 | 195.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
128.70 | 132.48 | 137.44 | 142.03 | |
Average Payables |
113.66 | 111.16 | 117.20 | 132.42 | |
Average Inventory |
38.10 | 41.46 | 41.22 | 39.85 | |
Average Assets |
1,022.56 | 1,018.37 | 1,020.53 | 1,094.95 | |
Average Common Equity |
350.32 | 346.34 | 343.77 | 345.97 |
Columns are period end dates · fundamentals updated 2 Nov 2026